Asunto(s)
Vacunas contra la COVID-19 , Industria Farmacéutica/historia , Investigadores/historia , Investigación/historia , Vacunas Sintéticas/historia , Animales , Ensayos Clínicos como Asunto , Industria Farmacéutica/economía , Terapia Genética/historia , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Liposomas , Ratones , Nanopartículas/química , Neoplasias/genética , Neoplasias/inmunología , Neoplasias/terapia , Premio Nobel , Patentes como Asunto/historia , Seudouridina/metabolismo , ARN/biosíntesis , ARN/genética , Estabilidad del ARN , Conejos , Glicoproteína de la Espiga del Coronavirus/química , Glicoproteína de la Espiga del Coronavirus/inmunología , Receptores Toll-Like/inmunología , Vacunas de ADN/historia , Vacunas Sintéticas/efectos adversos , Vacunas Sintéticas/uso terapéutico , Vacunas de ARNmRESUMEN
Seminal demonstration of the possibility of stable genetic modification of mammalian cells performed by Waclaw and Elisabeth Szybalski opened the doors for gene therapy, the term coined by Waclaw Szybalski already in 1962. In the next 60 years, numerous tools for gene delivery have been developed and applied for clinical research, culminating in the registration of several genetic therapies in Europe and the USA. Some of these strategies, aimed to treat severe combined immunodeficiencies, inherited forms of blindness, spinal muscular atrophy, some cancers, and genetic anemias, are the real hope for patients suffering from previously incurable diseases or the ones whose treatment was not effective. On the approaching 60th anniversary of gene therapy, combined with the 100th anniversary of the birth of Professor Waclaw Szybalski (September 9th, 1921), who passed away on December 16, 2020, here I present the summary of the most important aspects of clinical applications of genetic therapies.
Asunto(s)
Terapia Genética/historia , Animales , Europa (Continente) , Terapia Genética/métodos , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Ratones , Atrofia Muscular Espinal/historia , Atrofia Muscular Espinal/terapia , Inmunodeficiencia Combinada Grave/historia , Inmunodeficiencia Combinada Grave/terapia , Estados Unidos , Talasemia beta/historia , Talasemia beta/terapiaRESUMEN
Heritable human genome editing (HHGE) has become a topic of intense public interest, especially since 2015. In the early 1980s, a related topic-human genetic engineering-was the subject of sustained public discussion. There was particular concern about germline genetic intervention. During the 1980s debate, an advisory committee to the Director of the National Institutes of Health (NIH)-the Recombinant DNA Advisory Committee (RAC)-agreed to provide initial public review of proposals for deliberate introduction of DNA into human beings. In 1984 and 1985, the RAC developed guidelines for research involving DNA transfer into patients. The committee also commented on the possibility of deliberately altering the human germline. We track the textual changes over time in the RAC's response to the possibility of germline genetic intervention in humans. In 2019, the NIH RAC was abolished. New techniques for genome editing, including CRISPR-based techniques, make both somatic and germline alterations much more feasible. These novel capabilities have again raised questions about oversight. We propose the creation of a new structure for the public oversight of proposals to perform HHGE. In parallel with a technical review by a regulatory agency, such proposals should also be publicly evaluated by a presidentially appointed Bioethics Advisory Commission.
Asunto(s)
Edición Génica , Genoma Humano , Comités Consultivos , ADN Recombinante , Edición Génica/historia , Edición Génica/legislación & jurisprudencia , Edición Génica/métodos , Edición Génica/tendencias , Ingeniería Genética , Terapia Genética/historia , Terapia Genética/legislación & jurisprudencia , Terapia Genética/métodos , Terapia Genética/tendencias , Células Germinativas , Regulación Gubernamental , Historia del Siglo XX , Historia del Siglo XXI , Humanos , National Institutes of Health (U.S.) , Estados UnidosAsunto(s)
Terapia Genética , Estudios Clínicos como Asunto , Técnicas de Transferencia de Gen , Terapia Genética/historia , Terapia Genética/métodos , Terapia Genética/tendencias , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Investigación Biomédica Traslacional/historia , Investigación Biomédica Traslacional/métodos , Investigación Biomédica Traslacional/tendenciasAsunto(s)
Investigación Biomédica/historia , Cardiología/historia , Enfermedades Cardiovasculares/historia , Enfermedades Cardiovasculares/genética , Enfermedades Cardiovasculares/fisiopatología , Enfermedades Cardiovasculares/terapia , Terapia Genética/historia , Historia del Siglo XX , Historia del Siglo XXI , Humanos , ARN no Traducido/historiaAsunto(s)
Investigación Biomédica/historia , Cardiología/historia , Terapia Genética/historia , Cardiopatías/historia , ARN no Traducido/historia , Animales , Regulación de la Expresión Génica , Cardiopatías/genética , Cardiopatías/fisiopatología , Cardiopatías/terapia , Historia del Siglo XXI , Humanos , ARN no Traducido/genética , ARN no Traducido/uso terapéutico , RejuvenecimientoRESUMEN
Gapmers are antisense oligonucleotides composed of a central DNA segment flanked by nucleotides of modified chemistry. Hybridizing with transcripts by sequence complementarity, gapmers recruit ribonuclease H and induce target RNA degradation. Since its concept first emerged in the 1980s, much work has gone into developing gapmers for use in basic research and therapy. These include improvements in gapmer chemistry, delivery, and therapeutic safety. Gapmers have also successfully entered clinical trials for various genetic disorders, with two already approved by the U.S. Food and Drug Administration for the treatment of familial hypercholesterolemia and transthyretin amyloidosis-associated polyneuropathy. Here, we review the events surrounding the early development of gapmers, from conception to their maturity, and briefly conclude with perspectives on their use in therapy.
Asunto(s)
Invenciones/historia , Oligonucleótidos Antisentido/síntesis química , Oligonucleótidos Antisentido/historia , Animales , Investigación Biomédica/historia , Investigación Biomédica/métodos , ADN/administración & dosificación , ADN/química , ADN/metabolismo , Técnicas de Silenciamiento del Gen/historia , Técnicas de Silenciamiento del Gen/métodos , Terapia Genética/historia , Terapia Genética/métodos , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Oligonucleótidos Antisentido/metabolismo , Estabilidad del ARN , Ribonucleasa H/metabolismoRESUMEN
Long noncoding RNAs (lncRNAs) are a class of RNA with 200 nucleotides or longer that are not translated into protein. lncRNAs are highly abundant; a study estimates that at least four times more lncRNAs are typically present than coding RNAs in humans. However, function of more than 95% of human lncRNAs are still unknown. Synthetic antisense oligonucleotides called gapmers are powerful tools for lncRNA loss-of-function studies. Gapmers contain a central DNA part, which activates RNase H-mediated RNA degradation, flanked by modified oligonucleotides, such as 2'-O-methyl RNA (2'OMe), 2'-O-methoxyethyl RNA (2'MOE), constrained ethyl nucleosides (cEt), and locked nucleic acids (LNAs). In contrast to siRNA or RNAi-based methods, antisense oligonucleotide gapmer-based knockdown is often more effective against nuclear-localized lncRNA targets, since RNase H is mainly localized in nuclei. As such, gapmers are also potentially a powerful tool for therapeutics targeting lncRNAs in various diseases, including cancer, cardiovascular diseases, lung fibrosis, and neurological/neuromuscular diseases. This chapter will discuss the development and applications of gapmers for lncRNA loss-of-function studies and tips to design effective antisense oligonucleotides.
Asunto(s)
Técnicas de Silenciamiento del Gen/métodos , Oligonucleótidos Antisentido , ARN Largo no Codificante/genética , Animales , Enfermedades Cardiovasculares/genética , Enfermedades Cardiovasculares/terapia , Técnicas de Silenciamiento del Gen/historia , Terapia Genética/historia , Terapia Genética/métodos , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Atrofia Muscular Espinal/genética , Atrofia Muscular Espinal/terapia , Neoplasias/genética , Neoplasias/terapia , Oligonucleótidos Antisentido/síntesis química , Oligonucleótidos Antisentido/genética , Oligonucleótidos Antisentido/uso terapéutico , Fibrosis Pulmonar/genética , Fibrosis Pulmonar/terapia , ARN Largo no Codificante/antagonistas & inhibidoresRESUMEN
Although technological advances in molecular genetics over the last few decades have greatly expedited the identification of mutations in many genetic diseases, the translation of the genetic mechanisms into a clinical setting has been quite challenging, with a minimum number of effective treatments available. The advancements in antisense therapy have revolutionized the field of neuromuscular disorders as well as lipid-mediated diseases. With the approval of splice-switching antisense oligonucleotide (AO) therapy for nusinersen and eteplirsen for the treatment of spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD), several modified AOs are now being evaluated in clinical trials for the treatment of a number of disorders. In order to activate RNase H-mediated cleavage of the target mRNA, as well as to increase the binding affinity and specificity, gapmer AOs are designed that have a PS backbone flanked with the modified AOs on both sides. Mipomersen (trade name Kynamro), a 2'-O-methoxyethyl (MOE) gapmer, was approved by the Food and Drug Administration (FDA) for the treatment of homozygous familial hypercholesterolemia (HoFH) in 2013. Volanesorsen, another 20-mer MOE gapmer has shown to be successful in lowering the levels of triglycerides (TGs) in several lipid disorders and has received conditional approval in the European Union for the treatment of Familial chylomicronemia syndrome (FCS) in May 2019 following successful results from phase II/III clinical trials. This chapter focuses on the clinical applications of gapmer AOs for genetic dyslipidemia and lipodystrophy.
Asunto(s)
Desarrollo de Medicamentos , Dislipidemias/terapia , Lipodistrofia/terapia , Oligonucleótidos Antisentido/síntesis química , Oligonucleótidos Antisentido/uso terapéutico , Animales , Desarrollo de Medicamentos/historia , Desarrollo de Medicamentos/métodos , Dislipidemias/genética , Terapia Genética/historia , Terapia Genética/métodos , Terapia Genética/tendencias , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Lipodistrofia/genética , Morfolinos/síntesis química , Morfolinos/uso terapéutico , Oligonucleótidos/síntesis química , Oligonucleótidos/uso terapéutico , Oligonucleótidos Antisentido/genéticaRESUMEN
The concepts of gene therapy were initially introduced during the 1960s. Since the early 1990s, more than 1900 clinical trials have been conducted for the treatment of genetic diseases and cancers mainly using viral vectors. Although a variety of methods have also been performed for the treatment of malignant gliomas, it has been difficult to target invasive glioma cells. To overcome this problem, immortalized neural stem cell (NSC) and a nonlytic, amphotropic retroviral replicating vector (RRV) have attracted attention for gene delivery to invasive glioma. Recently, genome editing technology targeting insertions at site-specific locations has advanced; in particular, the clustered regularly interspaced palindromic repeats/CRISPR-associated-9 (CRISPR/Cas9) has been developed. Since 2015, more than 30 clinical trials have been conducted using genome editing technologies, and the results have shown the potential to achieve positive patient outcomes. Gene therapy using CRISPR technologies for the treatment of a wide range of diseases is expected to continuously advance well into the future.
Asunto(s)
Edición Génica/historia , Terapia Genética/historia , Neoplasias Encefálicas/terapia , Sistemas CRISPR-Cas , Edición Génica/instrumentación , Edición Génica/métodos , Terapia Genética/instrumentación , Terapia Genética/métodos , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Nucleasas de los Efectores Tipo Activadores de la TranscripciónAsunto(s)
Terapia Genética/historia , Dependovirus , Vectores Genéticos , Historia del Siglo XX , HumanosAsunto(s)
Terapia Genética/historia , Células HEK293 , Adenoviridae/genética , Historia del Siglo XX , Humanos , OncogenesRESUMEN
It is worth stating that a generation is needed to bring about a new family of drugs. After the deciphering of the genetic cause in 1995, two innovative classes of therapeutics are now available for spinal muscular atrophy (SMA): the repeated administration of antisens oligonucleotides and the one-shot administration of a scAAV9-SMN as a gene therapy. By addressing the genetic mechanisms of the disease, these drugs fundamentally change its course. These major advances in an extremely severe disease, often fatal before the age of 18 months in the type 1 form (50% of patients), pave the way for the treatment of other serious pathologies of the nervous or neuromuscular system, and provide unambiguous evidence of the effectiveness of these new classes of drugs called to address a number of genetic or acquired diseases. These breakthroughs raise also new scientific and technological questions (limited production yields of gene therapy drugs) but also ethical issues (access of patients to these innovative therapies) that resonate beyond this disease alone.
TITLE: Thérapies géniques de l'amyotrophie spinale infantile - Un morceau d'histoire de la médecine. ABSTRACT: On convient de dire qu'une génération est nécessaire pour faire émerger une nouvelle famille de médicaments. L'amyotrophie spinale infantile (SMA), après l'élucidation du gène causal en 1995, dispose depuis peu de deux classes innovantes de thérapeutiques : l'administration répétée d'oligonucléotides antisens et l'administration unique d'une thérapie génique par scAAV9-SMN. En s'adressant aux mécanismes génétiques de la maladie, elles en modifient fondamentalement le cours. Ces avancées majeures dans une maladie extrêmement sévère, mortelle souvent avant l'âge de 18 mois dans les formes de type 1 (50 % des malades), ouvrent la voie pour d'autres pathologies graves du système nerveux ou neuromusculaire, et apportent une preuve déterminante de l'efficacité de ces classes nouvelles de produits appelés à s'adresser à de nombreuses maladies génétiques ou acquises. Elles génèrent aussi de nouvelles questions d'ordre scientifique et technologique (capacités limitées de production des quantités nécessaires en thérapie génique) mais également d'ordre éthique (conditions d'accès des malades à ces thérapies innovantes), qui résonnent au-delà de cette seule maladie.
Asunto(s)
Terapia Genética/historia , Atrofia Muscular Espinal/genética , Atrofia Muscular Espinal/terapia , Animales , Dependovirus/genética , Dependovirus/fisiología , Modelos Animales de Enfermedad , Terapia Genética/economía , Terapia Genética/ética , Terapia Genética/métodos , Vectores Genéticos/síntesis química , Vectores Genéticos/economía , Vectores Genéticos/uso terapéutico , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Atrofia Muscular Espinal/economía , Atrofia Muscular Espinal/historia , Terapias en Investigación/economía , Terapias en Investigación/historia , Terapias en Investigación/métodos , Terapias en Investigación/tendenciasAsunto(s)
Enfermedades Cardiovasculares/historia , Edición Génica/historia , Terapia Genética/historia , Corazón , Regeneración , Investigación Biomédica Traslacional/historia , Animales , Enfermedades Cardiovasculares/genética , Enfermedades Cardiovasculares/fisiopatología , Enfermedades Cardiovasculares/terapia , Regulación del Desarrollo de la Expresión Génica , Corazón/fisiopatología , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Morfogénesis , Recuperación de la FunciónRESUMEN
This review presents many but not all the major historical events that have led to our current understanding of gene and stem cell therapies for the treatment of hearing and balance disorders in animal models of these disorders. In order to better understand the application of these emerging therapies to the treatment of inner ear disorders in a clinical setting, it has been necessary to provide some genetic and pathobiology backgrounds from both animal models and clinical disorders. The current focus and goal of gene and stem cell therapies are directed toward understanding the effective treatment of animal models that mimic human disorders of hearing and balance. This approach not only addresses the most effective ways to deliver the gene or stem cell therapies to affected inner ears, it also provides an assessment of the efficacy of the applied therapy(s) in achieving either partial or full restoration of either hearing and/or balance within the animal models receiving these therapeutic interventions. This review also attempts to present a realistic assessment of how close the research fields of gene and stem cell therapies are to application for the treatment of human disorders in a clinical setting. Progress made in developing these novel therapies toward clinical applications would not have been possible without the many pioneering studies and discoveries achieved by the investigators cited in this review. There were also many other excellent studies performed by gifted investigators that were not able to be included within this review. Anat Rec, 303:390-407, 2020. © 2019 American Association for Anatomy.